SCHEMBL3990334

SCHEMBL3990334

CCCCc1cc(O)c2sc(N)c(C(=O)OCC)c2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 12/20 0.51
▸ GAA P10253 6/20 0.51
▸ MEN1 O00255 5/20 0.51
▸ KMT2A Q03164 5/20 0.51
▸ ALOX15 P16050 4/20 0.51
▸ TSHR P16473 2/20 0.51
▸ MAPK1 P28482 4/20 0.48
▸ ALDH1A1 P00352 9/20 0.48
▸ HPGD P15428 8/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ USP2 O75604 1/20 0.47
▸ NPSR1 Q6W5P4 3/20 0.46
▸ FHIT P49789 1/20 0.45
▸ RAB9A P51151 3/20 0.43
▸ NPC1 O15118 2/20 0.43
▸ HTT P42858 1/20 0.42
▸ LMNA P02545 1/20 0.41
▸ ALOX12 P18054 1/20 0.41
▸ HSD17B10 Q99714 2/20 0.41
▸ NR1H2 P55055 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13848533 0.89 MAPT (0.49) MAPTGAAMEN1KMT2AALOX15
SCHEMBL13869870 0.88 MAPT (0.51) MAPTGAAMEN1KMT2AALOX15
SCHEMBL3982203 0.83 MAPT (0.64) MAPTGAAMEN1KMT2AALOX15
SCHEMBL3986612 0.81 MAPT (0.52) MAPTGAAMEN1KMT2AALOX15
SCHEMBL13886791 0.80 MAPT (0.49) MAPTGAAMEN1KMT2AALOX15
SCHEMBL3984848 0.76 MAPT (0.67) MAPTGAAMEN1KMT2AALOX15
SCHEMBL2925906 0.75 TSHR (0.67) MAPTGAAMEN1KMT2AALOX15
SCHEMBL13848534 0.74 MAPT (0.48) MAPTGAAMEN1KMT2AALOX15
SCHEMBL13869918 0.69 FHIT (0.41) MAPTGAATSHRMAPK1ALDH1A1
SCHEMBL13869878 0.69 MAPT (0.49) MAPTGAAMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7524853-B2 Compounds and their use in therapy SOLVAY PHARMACEUTICALS B.V. (NL) 2009-04-28 — — US disclosed
US-7524853-B2 Compounds and their use in therapy SOLVAY PHARMACEUTICALS B.V. (NL) 2009-04-28 — — US disclosed
US-7524853-B2 Compounds and their use in therapy SOLVAY PHARMACEUTICALS B.V. (NL) 2009-04-28 — — US disclosed
US-7465739-B2 Compounds and their use in therapy SOLVAY PHARMACEUTICALS B.V. (NL) 2008-12-16 — — US disclosed
US-7465739-B2 Compounds and their use in therapy SOLVAY PHARMACEUTICALS B.V. (NL) 2008-12-16 — — US disclosed
US-20050176742-A1 Novel compounds and their use in therapy SOLVAY PHARMACEUTICALS B.V. (NL) 2005-08-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176742-A1 Novel compounds and their use in therapy HSD17B11, HSD17B2, HSD17B1 MAPT 1642/4885GAA 519/4885MEN1 2028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback